Article Information
History
- February 12, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- David M. Patrick1,2,
- Nestor de la Visitación3,
- Michelle J. Ormseth4,
- C. Michael Stein1,4,
- Sean S. Davies1,
- Valery N. Yermalitksy1,
- Venkataraman Amarnath1,
- Leslie J. Crofford4,
- Jonathan M. Williams4,
- Sergey Dikalov1,
- Anna Dikalova1,
- Liang Xiao1,
- Justin P. Van Beusecum1,
- Mingfang Ao1,
- Agnes B. Fogo5,
- Annet Kirabo1 and
- David G. Harrison1,2,*
- 1Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- 2Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center
- 3Department of Pharmacology, University of Granada, Granada, Spain
- 4Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center
- 5Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center
- ↵*Address for correspondence:
David G. Harrison, MD, 220 Pierce Avenue, Room 536 Robinson Research Building, Vanderbilt University, Nashville, TN 37232-6602, Telephone: 615-322-3304/Fax: 615-875-3297, e-mail: David.g.harrison{at}vumc.org
Posted February 12, 2020.
Isolevuglandins promote autoimmunity and hypertension in systemic lupus erythematosus
